APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Osteoporosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Postmenopausal Osteoporosis Drugs Market Outlook and Growth Opportunities 2026

20 December 2025198 pages

Choose your research edition.

Industry ResearchPostmenopausal Osteoporosis Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Osteoporosis Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Postmenopausal Osteoporosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Osteoporosis Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Osteoporosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Postmenopausal Osteoporosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Postmenopausal Osteoporosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Postmenopausal Osteoporosis Drugs market include Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, PhytoHealth, Radius Health and Tarsa Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Postmenopausal Osteoporosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Postmenopausal Osteoporosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Postmenopausal Osteoporosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Postmenopausal Osteoporosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Postmenopausal Osteoporosis Drugs Segment by Company

Allergan

Amgen Astellas Biopharm

Deltanoid Pharmaceuticals

Noven

Novo Nordisk

Osteologix

PhytoHealth

Radius Health

Tarsa Therapeutics

Amgen

Pfizer

Eli Lilly

Merck

Novartis

Postmenopausal Osteoporosis Drugs Segment by Type

Antiresorptive Medications

Anabolic Medications

Postmenopausal Osteoporosis Drugs Segment by Application

Hospital

Pharmacy

Other

Postmenopausal Osteoporosis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Postmenopausal Osteoporosis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Postmenopausal Osteoporosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Postmenopausal Osteoporosis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Postmenopausal Osteoporosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Osteoporosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Postmenopausal Osteoporosis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Postmenopausal Osteoporosis Drugs industry.

Chapter 3: Detailed analysis of Postmenopausal Osteoporosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Postmenopausal Osteoporosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Postmenopausal Osteoporosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Postmenopausal Osteoporosis Drugs Industry Trends Table 2. Postmenopausal Osteoporosis Drugs Industry Drivers Table 3. Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges Table 4. Postmenopausal Osteoporosis Drugs Industry Restraints Table 5. Global Postmenopausal Osteoporosis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Postmenopausal Osteoporosis Drugs Revenue Share by Company (2021-2026) Table 7. Global Postmenopausal Osteoporosis Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Postmenopausal Osteoporosis Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Postmenopausal Osteoporosis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Postmenopausal Osteoporosis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Postmenopausal Osteoporosis Drugs Company, Product Type & Application Table 13. Global Postmenopausal Osteoporosis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Postmenopausal Osteoporosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antiresorptive Medications Table 18. Significant Companies of Anabolic Medications Table 19. Global Postmenopausal Osteoporosis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Postmenopausal Osteoporosis Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Postmenopausal Osteoporosis Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Postmenopausal Osteoporosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Postmenopausal Osteoporosis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Postmenopausal Osteoporosis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Type (2021-2026) Table 28. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Postmenopausal Osteoporosis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Postmenopausal Osteoporosis Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Postmenopausal Osteoporosis Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Postmenopausal Osteoporosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Postmenopausal Osteoporosis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Postmenopausal Osteoporosis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Application (2021-2026) Table 41. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Application (2027-2032) Table 42. Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2021-2026) Table 45. Global Postmenopausal Osteoporosis Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2027-2032) Table 47. Global Postmenopausal Osteoporosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Postmenopausal Osteoporosis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Region (2021-2026) Table 50. Global Postmenopausal Osteoporosis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Region (2027-2032) Table 52. Global Postmenopausal Osteoporosis Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Postmenopausal Osteoporosis Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Postmenopausal Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Postmenopausal Osteoporosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2021-2026) Table 58. Global Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2027-2032) Table 60. Global Postmenopausal Osteoporosis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Postmenopausal Osteoporosis Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Postmenopausal Osteoporosis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Postmenopausal Osteoporosis Drugs Sales Value Market Share by Country (2027-2032) Table 64. Allergan Company Information Table 65. Allergan Business Overview Table 66. Allergan Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Allergan Postmenopausal Osteoporosis Drugs Product Portfolio Table 68. Allergan Recent Development Table 69. Amgen Astellas Biopharm Company Information Table 70. Amgen Astellas Biopharm Business Overview Table 71. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio Table 73. Amgen Astellas Biopharm Recent Development Table 74. Deltanoid Pharmaceuticals Company Information Table 75. Deltanoid Pharmaceuticals Business Overview Table 76. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio Table 78. Deltanoid Pharmaceuticals Recent Development Table 79. Noven Company Information Table 80. Noven Business Overview Table 81. Noven Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Noven Postmenopausal Osteoporosis Drugs Product Portfolio Table 83. Noven Recent Development Table 84. Novo Nordisk Company Information Table 85. Novo Nordisk Business Overview Table 86. Novo Nordisk Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio Table 88. Novo Nordisk Recent Development Table 89. Osteologix Company Information Table 90. Osteologix Business Overview Table 91. Osteologix Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio Table 93. Osteologix Recent Development Table 94. PhytoHealth Company Information Table 95. PhytoHealth Business Overview Table 96. PhytoHealth Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio Table 98. PhytoHealth Recent Development Table 99. Radius Health Company Information Table 100. Radius Health Business Overview Table 101. Radius Health Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio Table 103. Radius Health Recent Development Table 104. Tarsa Therapeutics Company Information Table 105. Tarsa Therapeutics Business Overview Table 106. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio Table 108. Tarsa Therapeutics Recent Development Table 109. Amgen Company Information Table 110. Amgen Business Overview Table 111. Amgen Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Amgen Postmenopausal Osteoporosis Drugs Product Portfolio Table 113. Amgen Recent Development Table 114. Pfizer Company Information Table 115. Pfizer Business Overview Table 116. Pfizer Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio Table 118. Pfizer Recent Development Table 119. Eli Lilly Company Information Table 120. Eli Lilly Business Overview Table 121. Eli Lilly Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio Table 123. Eli Lilly Recent Development Table 124. Merck Company Information Table 125. Merck Business Overview Table 126. Merck Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Merck Postmenopausal Osteoporosis Drugs Product Portfolio Table 128. Merck Recent Development Table 129. Novartis Company Information Table 130. Novartis Business Overview Table 131. Novartis Postmenopausal Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Novartis Postmenopausal Osteoporosis Drugs Product Portfolio Table 133. Novartis Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Postmenopausal Osteoporosis Drugs Distributors List Table 137. Postmenopausal Osteoporosis Drugs Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Postmenopausal Osteoporosis Drugs Product Image Figure 2. Global Postmenopausal Osteoporosis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Osteoporosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Postmenopausal Osteoporosis Drugs Sales (2021-2032) & (K Units) Figure 5. Global Postmenopausal Osteoporosis Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Postmenopausal Osteoporosis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antiresorptive Medications Image Figure 10. Anabolic Medications Image Figure 11. Global Postmenopausal Osteoporosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Postmenopausal Osteoporosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Postmenopausal Osteoporosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Postmenopausal Osteoporosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Postmenopausal Osteoporosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Postmenopausal Osteoporosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Postmenopausal Osteoporosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Postmenopausal Osteoporosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Postmenopausal Osteoporosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Postmenopausal Osteoporosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Postmenopausal Osteoporosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Postmenopausal Osteoporosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Postmenopausal Osteoporosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Postmenopausal Osteoporosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Postmenopausal Osteoporosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Postmenopausal Osteoporosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Postmenopausal Osteoporosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Postmenopausal Osteoporosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Postmenopausal Osteoporosis Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Postmenopausal Osteoporosis Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Antiresorptive Medications
  • Anabolic Medications
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Allergan
  • Amgen Astellas Biopharm
  • Deltanoid Pharmaceuticals
  • Noven
  • Novo Nordisk
  • Osteologix
  • PhytoHealth
  • Radius Health
  • Tarsa Therapeutics
  • Amgen
  • Pfizer
  • Eli Lilly
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Postmenopausal Osteoporosis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Postmenopausal Osteoporosis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Postmenopausal Osteoporosis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Postmenopausal Osteoporosis Drugs Market Dynamics
  1. 2.1 Postmenopausal Osteoporosis Drugs Industry Trends
  2. 2.2 Postmenopausal Osteoporosis Drugs Industry Drivers
  3. 2.3 Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Osteoporosis Drugs Industry Restraints
3 Postmenopausal Osteoporosis Drugs Market by Company
  1. 3.1 Global Postmenopausal Osteoporosis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Postmenopausal Osteoporosis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Postmenopausal Osteoporosis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Postmenopausal Osteoporosis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Postmenopausal Osteoporosis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Postmenopausal Osteoporosis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Postmenopausal Osteoporosis Drugs Company Product Type and Application
  8. 3.8 Global Postmenopausal Osteoporosis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Postmenopausal Osteoporosis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Postmenopausal Osteoporosis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Postmenopausal Osteoporosis Drugs Market by Type
  1. 4.1 Postmenopausal Osteoporosis Drugs Type Introduction
  2. 4.1.1 Antiresorptive Medications
  3. 4.1.2 Anabolic Medications
  4. 4.2 Global Postmenopausal Osteoporosis Drugs Sales Volume by Type
  5. 4.2.1 Global Postmenopausal Osteoporosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Postmenopausal Osteoporosis Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Postmenopausal Osteoporosis Drugs Sales Value by Type
  9. 4.3.1 Global Postmenopausal Osteoporosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Postmenopausal Osteoporosis Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Postmenopausal Osteoporosis Drugs Sales Value Share by Type (2021-2032)
5 Postmenopausal Osteoporosis Drugs Market by Application
  1. 5.1 Postmenopausal Osteoporosis Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Postmenopausal Osteoporosis Drugs Sales Volume by Application
  6. 5.2.1 Global Postmenopausal Osteoporosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Postmenopausal Osteoporosis Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Postmenopausal Osteoporosis Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Postmenopausal Osteoporosis Drugs Sales Value by Application
  10. 5.3.1 Global Postmenopausal Osteoporosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Postmenopausal Osteoporosis Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Postmenopausal Osteoporosis Drugs Sales Value Share by Application (2021-2032)
6 Postmenopausal Osteoporosis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Postmenopausal Osteoporosis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Postmenopausal Osteoporosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Postmenopausal Osteoporosis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Postmenopausal Osteoporosis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Postmenopausal Osteoporosis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Postmenopausal Osteoporosis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Postmenopausal Osteoporosis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Postmenopausal Osteoporosis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Postmenopausal Osteoporosis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Postmenopausal Osteoporosis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Postmenopausal Osteoporosis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Postmenopausal Osteoporosis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Postmenopausal Osteoporosis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Postmenopausal Osteoporosis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Postmenopausal Osteoporosis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Postmenopausal Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Postmenopausal Osteoporosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Postmenopausal Osteoporosis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Postmenopausal Osteoporosis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Postmenopausal Osteoporosis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Postmenopausal Osteoporosis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Postmenopausal Osteoporosis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Postmenopausal Osteoporosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Postmenopausal Osteoporosis Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Amgen Astellas Biopharm
  8. 8.2.1 Amgen Astellas Biopharm Company Information
  9. 8.2.2 Amgen Astellas Biopharm Business Overview
  10. 8.2.3 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio
  12. 8.2.5 Amgen Astellas Biopharm Recent Developments
  13. 8.3 Deltanoid Pharmaceuticals
  14. 8.3.1 Deltanoid Pharmaceuticals Company Information
  15. 8.3.2 Deltanoid Pharmaceuticals Business Overview
  16. 8.3.3 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio
  18. 8.3.5 Deltanoid Pharmaceuticals Recent Developments
  19. 8.4 Noven
  20. 8.4.1 Noven Company Information
  21. 8.4.2 Noven Business Overview
  22. 8.4.3 Noven Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Noven Postmenopausal Osteoporosis Drugs Product Portfolio
  24. 8.4.5 Noven Recent Developments
  25. 8.5 Novo Nordisk
  26. 8.5.1 Novo Nordisk Company Information
  27. 8.5.2 Novo Nordisk Business Overview
  28. 8.5.3 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio
  30. 8.5.5 Novo Nordisk Recent Developments
  31. 8.6 Osteologix
  32. 8.6.1 Osteologix Company Information
  33. 8.6.2 Osteologix Business Overview
  34. 8.6.3 Osteologix Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio
  36. 8.6.5 Osteologix Recent Developments
  37. 8.7 PhytoHealth
  38. 8.7.1 PhytoHealth Company Information
  39. 8.7.2 PhytoHealth Business Overview
  40. 8.7.3 PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio
  42. 8.7.5 PhytoHealth Recent Developments
  43. 8.8 Radius Health
  44. 8.8.1 Radius Health Company Information
  45. 8.8.2 Radius Health Business Overview
  46. 8.8.3 Radius Health Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio
  48. 8.8.5 Radius Health Recent Developments
  49. 8.9 Tarsa Therapeutics
  50. 8.9.1 Tarsa Therapeutics Company Information
  51. 8.9.2 Tarsa Therapeutics Business Overview
  52. 8.9.3 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio
  54. 8.9.5 Tarsa Therapeutics Recent Developments
  55. 8.10 Amgen
  56. 8.10.1 Amgen Company Information
  57. 8.10.2 Amgen Business Overview
  58. 8.10.3 Amgen Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Amgen Postmenopausal Osteoporosis Drugs Product Portfolio
  60. 8.10.5 Amgen Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Eli Lilly
  68. 8.12.1 Eli Lilly Company Information
  69. 8.12.2 Eli Lilly Business Overview
  70. 8.12.3 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio
  72. 8.12.5 Eli Lilly Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Merck Postmenopausal Osteoporosis Drugs Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Novartis
  80. 8.14.1 Novartis Company Information
  81. 8.14.2 Novartis Business Overview
  82. 8.14.3 Novartis Postmenopausal Osteoporosis Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Novartis Postmenopausal Osteoporosis Drugs Product Portfolio
  84. 8.14.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Postmenopausal Osteoporosis Drugs Value Chain Analysis
  2. 9.1.1 Postmenopausal Osteoporosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Postmenopausal Osteoporosis Drugs Sales Mode & Process
  6. 9.2 Postmenopausal Osteoporosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Postmenopausal Osteoporosis Drugs Distributors
  9. 9.2.3 Postmenopausal Osteoporosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst